Technical Analysis for APLS - Apellis Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
F 31.4 -3.12% -1.01
APLS closed down 3.12 percent on Friday, September 24, 2021, on 61 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down
Historical APLS trend table...

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Down 5 Days in a Row Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Narrow Range Bar Range Contraction -3.12%
NR7 Range Contraction -3.12%
Doji - Bullish? Reversal -3.12%
Wide Bands Range Expansion -3.12%
Older End-of-Day Signals for APLS ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Apellis Pharmaceuticals, Inc. Description

Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. The Company's lead compounds are designed to inhibit complement component 3 (C3), the central protein in the complement cascade. The Company is developing APL-2 for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) by subcutaneous injection, which is an injection into the tissue under the skin. It is developing APL-2 for the treatment of geographic atrophy (GA) and intermediate age-related macular degeneration (AMD) by intravitreal injection, which is an injection into the eye. The Company is developing APL-1 for the treatment of chronic obstructive pulmonary disease (COPD) by inhaled administration.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Clinical Medicine Eye Organ Systems Inflammatory Disease Inflammatory Diseases Macular Degeneration Related Macular Degeneration Pulmonary Disease Chronic Obstructive Pulmonary Disease Hemoglobin Autoimmune And Inflammatory Diseases Autoimmune And Inflammatory Disease Complement System C3 Hemoglobinuria Paroxysmal Nocturnal Hemoglobinuria Treatment Of Chronic Obstructive Pulmonary Disease Acquired Hemolytic Anemia Intravitreal Administration Pnh Copd Intravitreal Injection

Is APLS a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 73.0
52 Week Low 27.5
Average Volume 1,656,895
200-Day Moving Average 52.27
50-Day Moving Average 55.99
20-Day Moving Average 46.18
10-Day Moving Average 32.97
Average True Range 3.22
ADX 46.65
+DI 8.09
-DI 44.96
Chandelier Exit (Long, 3 ATRs) 58.04
Chandelier Exit (Short, 3 ATRs) 37.17
Upper Bollinger Bands 75.56
Lower Bollinger Band 16.81
Percent B (%b) 0.25
BandWidth 127.21
MACD Line -7.98
MACD Signal Line -6.92
MACD Histogram -1.056
Fundamentals Value
Market Cap 2.37 Billion
Num Shares 75.6 Million
EPS -3.32
Price-to-Earnings (P/E) Ratio -9.45
Price-to-Sales 4846.49
Price-to-Book 33.50
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 33.68
Resistance 3 (R3) 33.90 33.36 33.30
Resistance 2 (R2) 33.36 32.78 33.25 33.17
Resistance 1 (R1) 32.38 32.42 32.11 32.16 33.05
Pivot Point 31.84 31.84 31.71 31.73 31.84
Support 1 (S1) 30.86 31.26 30.59 30.64 29.75
Support 2 (S2) 30.32 30.90 30.21 29.63
Support 3 (S3) 29.34 30.32 29.50
Support 4 (S4) 29.12